Literature DB >> 30620402

Cancer statistics, 2019.

Rebecca L Siegel1, Kimberly D Miller2, Ahmedin Jemal3.   

Abstract

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers. For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016. Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.
© 2019 American Cancer Society.

Entities:  

Keywords:  cancer cases; cancer statistics; death rates; incidence; mortality

Mesh:

Year:  2019        PMID: 30620402     DOI: 10.3322/caac.21551

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  PDLIM5 inhibits STUB1-mediated degradation of SMAD3 and promotes the migration and invasion of lung cancer cells.

Authors:  Yueli Shi; Xinyu Wang; Zhiyong Xu; Ying He; Chunyi Guo; Lingjuan He; Caijuan Huan; Changhong Cai; Jiaqi Huang; Jie Zhang; Yiqing Li; Chunlai Zeng; Xue Zhang; Linrun Wang; Yuehai Ke; Hongqiang Cheng
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

2.  Silencing of miR490-3p by H. pylori activates DARPP-32 and induces resistance to gefitinib.

Authors:  Shoumin Zhu; Shayan Khalafi; Zheng Chen; Julio Poveda; Dunfa Peng; Heng Lu; Mohammed Soutto; Jianwen Que; Monica Garcia-Buitrago; Alexander Zaika; Wael El-Rifai
Journal:  Cancer Lett       Date:  2020-07-29       Impact factor: 8.679

Review 3.  X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.

Authors:  Rossella Tricarico; Emmanuelle Nicolas; Michael J Hall; Erica A Golemis
Journal:  Clin Cancer Res       Date:  2020-07-30       Impact factor: 12.531

4.  Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.

Authors:  Pierre-Olivier Gaudreau; J Jack Lee; John V Heymach; Don L Gibbons
Journal:  Clin Lung Cancer       Date:  2020-03-04       Impact factor: 4.785

5.  Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data.

Authors:  Chad Tang; Xiudong Lei; Grace L Smith; Hubert Y Pan; Kenneth Hess; Aileen Chen; Karen E Hoffman; Brian F Chapin; Deborah A Kuban; Mitchell Anscher; Ya-Chen Tina Shih; Steven J Frank; Benjamin D Smith
Journal:  Pract Radiat Oncol       Date:  2020-04-13

6.  Fluorometric immunoassay for the simultaneous determination of the tumor markers carcinoembryonic antigen and cytokeratin 19 fragment using two kinds of CdSe/ZnS quantum dot nanobeads and magnetic beads.

Authors:  Lihua Ding; Xiao Chen; Leiliang He; Fei Yu; Songcheng Yu; Jia Wang; Yongmei Tian; Yilin Wang; Yongjun Wu; Li-E Liu; Lingbo Qu
Journal:  Mikrochim Acta       Date:  2020-02-15       Impact factor: 5.833

7.  Leveraging Digital Data to Inform and Improve Quality Cancer Care.

Authors:  Tina Hernandez-Boussard; Douglas W Blayney; James D Brooks
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-17       Impact factor: 4.254

Review 8.  Exosomal biomarkers for cancer diagnosis and patient monitoring.

Authors:  Amy Makler; Waseem Asghar
Journal:  Expert Rev Mol Diagn       Date:  2020-02-20       Impact factor: 5.225

9.  General Health Care Utilization Among Nonelderly Cancer Survivors Before and After Affordable Care Act Implementation: Early Results.

Authors:  Amy L Shaver; Ying Cao; Katia Noyes
Journal:  JCO Oncol Pract       Date:  2020-02-18

10.  Evaluation of models for predicting the probability of malignancy in patients with pulmonary nodules.

Authors:  You Li; Hui Hu; Ziwei Wu; Ge Yan; Tangwei Wu; Shuiyi Liu; Weiqun Chen; Zhongxin Lu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.